DKK440.9 6.5 1.5%
Last Trade - 3:16pm
| Market Cap | £117.11bn |
| Enterprise Value | £116.83bn |
| Revenue | £14.80bn |
| Position in Universe | 2nd / 1830 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 107,927 | 111,780 | 111,696 | 111,831 | 122,021 | 126,946 | 132,264 | 144,655 | +3.3% | ||
| +24.3 | +18.7 | +2.3 | +2.9 | +5.3 | +8.3 | +5.66 | +12.2 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | November 28, 1931 |
| Public Since | May 17, 1974 |
| No. of Shareholders: | n/a |
| No. of Employees: | 44,723 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 300 , FTSEurofirst 300 Ex Eurozone, FTSEurofirst 300 Ex UK, FTSE Global 100, |
| Exchange | OMX Nordic Exchange - Copenhagen |
| Shares in Issue | 2,312,500,000 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Novo Alle 1, BAGSVAERD, 2880, Denmark |
| Web | https://www.novonordisk.com/ |
| Phone | +45 44 448888 |
| Contact | Peter Hugreffe Ankersen (Corporate Vice President and Head of Investor Relations) |
| Auditors | PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELS |
As of 3:16pm, shares in Novo Nordisk A/S are trading at DKK440.9, giving the company a market capitalisation of £117.11bn. This share price information is delayed by 15 minutes.
Shares in Novo Nordisk A/S are currently trading at DKK440.9 and the price has moved by 6.88% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Novo Nordisk A/S price has moved by -16.84% over the past year.
Of the analysts with advisory recommendations for Novo Nordisk A/S, there are there are currently 4 "buy" , 10 "hold" and 2 "sell" recommendations. The overall consensus recommendation for Novo Nordisk A/S is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Novo Nordisk A/S is scheduled to issue upcoming financial results on the following dates:
The Novo Nordisk A/S dividend yield is 2.09% based on the trailing twelve month period.
Last year, Novo Nordisk A/S paid a total dividend of 9.1, and it currently has a trailing dividend yield of 2.09%. Looking ahead, Novo Nordisk A/S has not announced an ex-dividend date yet.
Novo Nordisk A/S has yet to annouce their ex-dividend date. The historic dividend yield on Novo Nordisk A/S shares is currently 2.09%.
To buy shares in Novo Nordisk A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Novo Nordisk A/S are currently trading at DKK440.9, giving the company a market capitalisation of £117.11bn.
Here are the trading details for Novo Nordisk A/S:
Based on an overall assessment of its quality, value and momentum, Novo Nordisk A/S is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Novo Nordisk A/S are currently priced at DKK440.9. At that level they are trading at 6.79% discount to the analyst consensus target price of 0.00.
Analysts covering Novo Nordisk A/S currently have a consensus Earnings Per Share (EPS) forecast of 19.197 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novo Nordisk A/S. Over the past six months, the relative strength of its shares against the market has been -20.8%. At the current price of DKK440.9, shares in Novo Nordisk A/S are trading at 0.49% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Novo Nordisk A/S PE ratio based on its reported earnings over the past 12 months is 23.91. The shares are currently trading at DKK440.9.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Novo Nordisk A/S's management team is headed by:
Here are the top five shareholders of Novo Nordisk A/S based on the size of their shareholding:
